Protagonist Therapeutics (PTGX) Current Leases (2019 - 2026)

Protagonist Therapeutics has disclosed Current Leases across 8 years of filings, most recently posting $2.3 million for Q1 2026.

• Current Leases for Q1 2026 came in at $2.3 million, up 49.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 49.17% YoY), and the FY2025 annual result was $2.3 million, up 347.65% from the prior year.
• Current Leases came in at $2.3 million for Q1 2026 at Protagonist Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.6 million in Q1 2023 to a low of $45000.0 in Q3 2024.
• The 5-year median for Current Leases is $2.3 million (2022), against an average of $1.8 million.
• Across the five-year window, Current Leases plunged 97.5% in 2024 and jumped 4851.11% in 2025, its largest moves.
• Protagonist Therapeutics' Current Leases stood at $2.5 million in 2022, then plunged by 54.63% to $1.1 million in 2023, then tumbled by 55.3% to $510000.0 in 2024, then soared by 347.65% to $2.3 million in 2025, then climbed by 2.45% to $2.3 million in 2026.
• The last three Current Leases figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.